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Background
Infants with cyanotic congenital heart disease palliated with placement of a systemic-
to-pulmonary-artery shunt are at risk for shunt thrombosis and death. We investi-
gated whether the addition of clopidogrel to conventional therapy reduces mortality 
from any cause and morbidity related to the shunt.
Methods
In a multicenter, double-blind, event-driven trial, we randomly assigned infants 92 
days of age or younger with cyanotic congenital heart disease and a systemic-to-pul-
monary-artery shunt to receive clopidogrel at a dose of 0.2 mg per kilogram of body 
weight per day (467 infants) or placebo (439 infants), in addition to conventional 
therapy (including aspirin in 87.9% of infants). The primary efficacy end point was 
a composite of death or heart transplantation, shunt thrombosis, or performance of 
a cardiac procedure due to an event considered to be thrombotic in nature before 120 
days of age.
Results
The rate of the composite primary end point did not differ significantly between the 
clopidogrel group (19.1%) and the placebo group (20.5%) (absolute risk difference, 
1.4 percentage points; relative risk reduction with clopidogrel, 11.1%; 95% confi-
dence interval, –19.2 to 33.6; P = 0.43), nor did the rates of the three components of 
the composite primary end point. There was no significant benefit of clopidogrel 
treatment in any subgroup, including subgroups defined by shunt type. Clopidogrel 
recipients and placebo recipients had similar rates of overall bleeding (18.8% and 
20.2%, respectively) and severe bleeding (4.1% and 3.4%, respectively).
Conclusions
Clopidogrel therapy in infants with cyanotic congenital heart disease palliated with 
a systemic-to-pulmonary-artery shunt, most of whom received concomitant aspirin 
therapy, did not reduce either mortality from any cause or shunt-related morbidity. 
(Funded by Sanofi-Aventis and Bristol-Myers Squibb; ClinicalTrials.gov number, 
NCT00396877.)
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Congenital heart disease is the most common type of birth defect and a com-mon cause of death in the first year of 
life.1,2 Although many forms of congenital heart 
disease can be repaired in early infancy, provi-
sion of pulmonary blood flow with a systemic-to-
pulmonary-artery shunt remains an essential 
component of initial treatment for some forms of 
complex cyanotic congenital heart disease. Shunts 
are most commonly placed for primary palliation 
or as a component of staged reconstruction in 
infants with single-ventricle disease, such as a 
hypoplastic left ventricle.3,4 They are also used 
as initial palliation for two-ventricle disease 
when the risk of definitive repair in early infancy 
is high.5
Infants who undergo placement of a systemic-
to-pulmonary-artery shunt for palliation are at 
risk for shunt thrombosis and sudden death.6-8 
Effective preventive therapy for thrombosis in 
young infants has not been tested in a random-
ized trial, but aspirin treatment has been associ-
ated with significantly reduced risks of mortality 
and shunt thrombosis in a prospective regis-
try.6,9 In adults with atherosclerotic cardiovascu-
lar disease, prophylactic antiplatelet therapy of-
ten consists of a combination of aspirin and the 
thienopyridine clopidogrel.10-13 As happens with 
many drugs that are approved for use in adults, 
clopidogrel use is spreading into pediatric prac-
tice in the absence of sound evidence of its ef-
ficacy in the pediatric population. Indeed, clopi-
dogrel use increased by a factor of 15 from 2001 
to 2009 in children’s hospitals in the United 
States.14 Some pediatric cardiovascular practi-
tioners have already claimed that clopidogrel is 
safe and effective on the basis of retrospective 
single-center reviews.15
The objective of our trial was to evaluate the 
efficacy of clopidogrel as compared with placebo 
in reducing mortality from any cause and shunt-
related morbidity in young infants with cyanotic 
congenital heart disease palliated with a systemic-
to-pulmonary-artery shunt. The safety of clopido-
grel was also evaluated on the basis of adverse 
events, especially those related to bleeding.
Me thods
Study Design
The Clopidogrel to Lower Arterial Thrombotic 
Risk in Neonates and Infants Trial (CLARINET) 
was a double-blind, randomized, placebo-con-
trolled, parallel-group, event-driven trial. The origi-
nal study design was developed by two of the aca-
demic authors in conjunction with representatives 
of the sponsors, Sanofi-Aventis and Bristol-Myers 
Squibb. The trial was designed in consultation with 
the Food and Drug Administration as part of the 
written request process for pediatric exclusivity 
(a 6-month extension of patent protection for drugs 
studied in children). The investigators at each study 
site gathered the data. The steering committee 
had unrestricted access to the raw data and par-
ticipated in the analysis, which was performed by 
statisticians employed by the sponsors. The pri-
mary end point was additionally validated by stat-
isticians who were not employed by the sponsor, 
and the final interpretation of data was provided 
by the steering committee. The first draft of the 
manuscript was written by two of the academic 
authors and subsequently revised by all the au-
thors. The academic authors vouch for the accu-
racy and completeness of the data and all analy-
ses, and for the fidelity of this report to the trial 
protocol, which is available with the full text of 
this article at NEJM.org.
Patients
Patients were recruited and followed from Novem-
ber 2006 through February 2010 at 134 sites in 
Europe, Asia, North America, South America, and 
Africa. Infants 92 days of age or younger at the 
time of randomization were eligible if they had 
cyanotic congenital heart disease palliated with a 
systemic-to-pulmonary-artery shunt (i.e., a mod-
ified Blalock–Taussig shunt, right ventricular-to-
pulmonary shunt, central shunt, or stent of duc-
tus arteriosus). Patients were excluded if they had 
active bleeding or had an increased risk of bleed-
ing; a full list of exclusion criteria is provided in 
the Supplementary Appendix, available at NEJM 
.org. Before randomization, written informed con-
sent was obtained from a parent or legal guard-
ian of each patient in accordance with the guide-
lines of local institutional review boards, which 
approved the study protocol.
Study Procedures
After shunt placement and as soon as possible 
within a 92-day window, infants were randomly 
assigned, in a 1:1 ratio, to receive clopidogrel 
(Plavix, Bristol-Myers Squibb and Sanofi-Aventis) 
at a dose of 0.2 mg per kilogram of body weight 
per day or matching placebo. Randomization was 
performed with the use of a central interactive 
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voice response system, with stratification accord-
ing to center only. The study drug was formulated 
as a syrup (see the Supplementary Appendix). Con-
comitant aspirin use was permitted, but the use 
of nonsteroidal anti-inflammatory drugs was dis-
couraged.
Efficacy and safety assessments were conducted 
by means of scheduled telephone contact, as well 
as in-person evaluations at baseline (day 1); at 
weeks 4, 12, 24, and 36; and at the final visit, de-
fined as the time of the first occurrence of an 
event marking termination of the study (shunt 
thrombosis, performance of elective surgery for 
correction of the congenital heart disease, death, 
the first birthday, or the common study end date). 
Compliance with study medication was assessed 
on the basis of study drugs returned to the study 
investigator at the end of each 12-week period. If 
necessary, treatment with the study drug could be 
temporarily discontinued and reinitiated. Tempo-
rary discontinuation for more than 2 consecutive 
days was recorded on the case report form. It 
was recommended that treatment be discontin-
ued 5 days before elective surgery.
End Points
The primary efficacy end point was defined as 
the earliest occurrence of any of the following: 
death or heart transplantation, shunt thrombosis 
requiring intervention, or a cardiac procedure per-
formed before 120 days of age because of an 
event adjudicated to be thrombotic. The third 
component was ascertained by an event-adjudi-
cation committee whose members were unaware 
of the group assignments. Detailed definitions of 
end-point events and a description of the event-
adjudication process are provided in the Supple-
mentary Appendix.
We analyzed adverse events and serious adverse 
events, including reports of any bleeding. Bleed-
ing events were classified according to their in-
tensity as judged by the investigator: mild, if they 
required no active intervention other than with-
holding medication or monitoring; moderate, if 
they required medical intervention to treat bleed-
ing or clot formation; and severe, if they required 
any procedural intervention.
Statistical Analysis
We assumed a rate of the primary end point of 
40% in the placebo group, on the basis of data 
compiled at several of the participating centers. 
Using this estimate, we designed the study to de-
tect a 30% relative reduction in the primary event 
rate in the clopidogrel group, with a statistical pow-
er of 80% and a 5% overall type I error rate. Interim 
analyses were performed when approximately 40%, 
60%, and 80% of the required 172 events oc-
curred. The data and safety monitoring commit-
tee recommended continuing the study after each 
interim analysis. At the final analysis, a P value 
of less than 0.035 was considered to indicate sta-
tistical significance.
The intention-to-treat principle was applied to 
all efficacy analyses. The time to occurrence of 
the primary end point was compared between 
the two study groups with the use of a two-sided 
log-rank test. Study-group comparisons were ex-
pressed as the relative risk reduction with clopid-
ogrel versus placebo and the corresponding 95% 
confidence interval, estimated with the use of a 
Cox proportional-hazards model. The Cox propor-
tional-hazards model was also used to assess the 
relationship between the treatment effect and the 
following prespecified characteristics: age (neo-
nates vs. older infants), sex, race or ethnic group, 
age at the time of shunt palliation (≤1 week vs. 
>1 week), interval between shunt palliation and 
randomization, type of initial surgery, type of car-
diac defect, and status with respect to prior and 
concomitant aspirin use.
Adverse events were analyzed in the popula-
tion of patients who received one or more doses 
of the study drug and also in the per-protocol 
population. The Pearson chi-square test was 
used to compare the rates of adverse events oc-
curring during treatment in the clopidogrel and 
placebo groups.
R esult s
Randomization and Follow-up
A total of 906 patients were enrolled and random-
ly assigned to either clopidogrel or placebo (Fig. 1). 
The baseline characteristics and time from shunt 
palliation to randomization were similar in the 
two study groups (Table 1); administration of other 
medications (including aspirin) and compliance 
with medication were also similar between the 
two groups. Aspirin was administered in 87.0% of 
placebo recipients and 88.7% of clopidogrel recipi-
ents as part of routine care.
The median duration of follow-up, which was 
similar in the two groups, was 5.8 months over-
all (range, 0 to 12). Study-drug administration was 
temporarily suspended in 53.6% of the patients for 
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a median of 8 days (range, 2 to 156). The study 
drug was permanently discontinued early in a sig-
nificantly greater proportion of patients receiving 
clopidogrel than patients receiving placebo (24.0% 
vs. 18.2%, P = 0.03) (Fig. 1); the overall median time 
to permanent discontinuation was 96 days (range, 
2 to 312). Reasons for premature study termina-
tion were similar in the two groups (Fig. 1).
Efficacy End Points
The primary end point occurred in 89 clopidogrel 
recipients and 90 placebo recipients (19.1% and 
20.5%, respectively; absolute risk difference, 1.4 
percentage points; relative risk reduction with clo-
pidogrel, 11.1%; 95% confidence interval [CI], –19.2 
to 33.6; P = 0.43) (Table 2 and Fig. 2). We further 
analyzed each component of the primary end 
point. The rate of heart transplantation or death 
from any cause was slightly lower with clopido-
grel than with placebo (11.8% vs. 13.9%), but this 
difference did not reach statistical significance 
(Table 2, and Fig. S1 in the Supplementary Ap-
pendix). The rates of death and heart transplan-
tation according to specific causes were similar 
in the two groups (Table 2), as were the incidence 
of shunt thrombosis and the rate of cardiac pro-
cedures performed before 120 days of age and 
related to thrombotic events (Table 2, and Fig. S2 
and S3 in the Supplementary Appendix).
In post hoc analyses, patients in the overall 
study population who received concomitant aspi-
rin, as compared with those who did not, had a 
significantly lower rate of the primary end point 
(18.6% vs. 28.2%; absolute risk difference, 9.6 
percentage points; relative risk reduction, 40.1%; 
95% CI, 11.8 to 59.3; P = 0.009 by the log-rank test) 
(Table S1 in the Supplementary Appendix).
We explored the effect of clopidogrel on effi-
cacy end points in prespecified subgroup analyses. 
There was no significant interaction between 
study-group assignment and the incidence of the 
primary end point in subgroups defined by age, 
sex, race or ethnic group, type of palliative surgery, 
number of days from palliation to randomization, 
type of cardiac defect, or status with respect to 
aspirin use before or during the study (Fig. S4 in 
the Supplementary Appendix). Event rates for the 
primary efficacy end point according to whether 
the patient received no antiplatelet therapy, aspi-
rin alone, clopidogrel alone, or aspirin plus clopid-
ogrel are presented in Fig. S5 and Table S2 in the 
Supplementary Appendix.
Safety End Points
Among all randomized patients who received one 
or more doses of the study drug, at least one ad-
verse event of any severity occurred in 353 patients 
(76.1%) in the clopidogrel group and 310 (71.1%) 
in the placebo group (P = 0.09); serious adverse 
events occurred in 234 patients (50.4%) in the 
clopidogrel group and 196 (45.0%) in the placebo 
group (P = 0.10) (Table S3 in the Supplementary 
Appendix). The percentage of patients with adverse 
events leading to permanent treatment discontin-
uation was similar in the clopidogrel group and 
the placebo group (7.3% and 7.1%, respectively; 
P = 0.90). More neurologic events occurred in the 
clopidogrel group than in the placebo group — 
most notably, seizure (in 14 patients [3.0%] vs. 
7 [1.6%]) and stroke (in 8 patients [1.7%] vs. 0).
Overall, approximately one in five patients had 
at least one bleeding episode (18.8% in the clo-
pidogrel group and 20.2% in the placebo group) 
(Fig. 3). The two groups did not differ signifi-
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Figure 1. Enrollment and Follow-up of the Study Patients, According to 
Study Group.
“Other reasons” for early discontinuation of study drug included the inves-
tigator’s decision to discontinue the study drug more than 5 days before 
surgery because of the risk of bleeding (in 36 patients in the clopidogrel 
group and 27 patients in the placebo group).
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Table 1. Baseline Characteristics of the Intention-to-Treat Population, According to Study Group.*
Characteristic
Clopidogrel 
(N = 467)
Placebo 
(N = 439)
Total  
(N = 906)
Age — days 36.1±22.3 36.0±22.5 36.1±22.4
Male sex — no. (%) 269 (57.6) 254 (57.9) 523 (57.7)
Weight — kg 3.4±0.7 3.5±0.7 3.5±0.7
Congenital cardiac defect — no. (%)
Hypoplastic left heart syndrome 120 (25.7) 104 (23.7) 224 (24.7)
Pulmonary atresia with intact ventricular septum 75 (16.1) 77 (17.5) 152 (16.8)
Tetralogy of Fallot 42 (9.0) 31 (7.1) 73 (8.1)
Tetralogy of Fallot with pulmonary atresia 63 (13.5) 62 (14.1) 125 (13.8)
Tricuspid atresia 49 (10.5) 56 (12.8) 105 (11.6)
Other single-ventricle defect 81 (17.3) 70 (15.9) 151 (16.7)
Other two-ventricle defect 61 (13.1) 64 (14.6) 125 (13.8)
Ebstein’s anomaly 11 (2.4) 8 (1.8) 19 (2.1)
Cardiac arrest before surgery — no. (%) 7 (1.5) 7 (1.6) 14 (1.5)
Type of initial systemic-to-pulmonary-artery shunt — no. (%)†
Modified Blalock–Taussig shunt
With Norwood procedure 62 (13.3) 51 (11.6) 113 (12.5)
Without Norwood procedure 257 (55.0) 252 (57.4) 509 (56.2)
Right ventricular-to-pulmonary shunt
With Norwood procedure 60 (12.8) 54 (12.3) 114 (12.6)
Without Norwood procedure 5 (1.1) 2 (0.5) 7 (0.8)
Central shunt 40 (8.6) 38 (8.7) 78 (8.6)
Stent in ductus arteriosus 42 (9.0) 42 (9.6) 84 (9.3)
Age at shunt palliation — days
Median 8.0 8.0 8.0
Range 0–92 0–91 0–92
Time from shunt palliation to randomization — no. (%)
≤1 wk 113 (24.2) 116 (26.4) 229 (25.3)
>1 to ≤2 wk 126 (27.0) 105 (23.9) 231 (25.5)
>2 to ≤4 wk 119 (25.5) 117 (26.7) 236 (26.0)
>4 wk 109 (23.3) 101 (23.0) 210 (23.2)
Duration of follow-up — mo
Median 5.9 5.6 5.8
Range 0–12 0–12 0–12
Duration of treatment — days
Median 162.0 161.5 —
Range 2–367 1–371
Aspirin use within 10 days before randomization — no. (%) 389 (83.3) 371 (84.5) 760 (83.9)
* Plus–minus values are means ±SD. There were no significant differences (P<0.05) between the two study groups in any 
of the characteristics listed.
† Data do not include one infant, in the clopidogrel group, with tetralogy of Fallot and pulmonary atresia who twice under-
went stenting of the right ventricular outflow tract but did not undergo palliation with a systemic-to-pulmonary-artery 
shunt.
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cantly with respect to the incidence of mild, mod-
erate, or severe bleeding (Table S4 in the Supple-
mentary Appendix). The majority of bleeding 
events were spontaneous, and the most common 
sites of bleeding were gastrointestinal. The num-
bers of bleeding events and other adverse events 
were consistent across the prespecified subgroups 
defined by age, sex, race or ethnic group, type of 
palliative surgery, days from palliation to ran-
domization, and status with respect to aspirin use 
before or during the study. Bleeding complica-
tions according to use or nonuse of concomitant 
aspirin therapy are summarized in Table S5 in the 
Supplementary Appendix.
In per-protocol analyses, adverse events oc-
curred in 260 patients (73.9%) in the clopidogrel 
group and 238 patients (66.9%) in the placebo 
group (P = 0.04) (Table S6 in the Supplementary 
Appendix). (The results of per-protocol analyses of 
bleeding events and events according to use or 
nonuse of concomitant aspirin therapy are given in 
Tables S7 and S8 in the Supplementary Appendix.)
Discussion
Our trial shows that adding clopidogrel to con-
ventional therapy did not reduce mortality from 
any cause or shunt-related morbidity in neonates 
or infants with congenital heart disease palliated 
with a systemic-to-pulmonary-artery shunt. The 
rate of the primary end point (the earliest occur-
rence of death or heart transplantation, shunt 
thrombosis, or a cardiac procedure before 120 days 
of age after an event considered to be thrombotic 
in nature) was similar with clopidogrel and pla-
cebo. The study did not show the efficacy of clo-
pidogrel for any component of the composite 
primary end point, including shunt thrombosis.
There are several plausible explanations for our 
finding that clopidogrel lacked clinical efficacy as 
compared with placebo. Cyanotic congenital heart 
disease comprises a heterogeneous group of dis-
orders that are managed in diverse ways.16 The 
percentage of the variance in end points explained 
by any single factor, such as use of a medication, 
Table 2. Incidence of the Primary Efficacy End Point in the Intention-to-Treat Population, According to Study Group.
End Point
Clopidogrel 
(N = 467)
Placebo 
(N = 439)
Absolute Risk 
Difference
Relative Risk Reduction 
with Clopidogrel P Value
no. of patients/total no. (%) percentage points percent (95% CI)
Primary end point* 89 (19.1) 90 (20.5) 1.4 11.1 (–19.2 to 33.6) 0.43
Death or heart transplantation 55 (11.8) 61 (13.9) 2.1 19.4 (–16.1 to 44.0) 0.25
Death from cardiovascular cause 27 (5.8) 28 (6.4) — —
Death related to cardiac procedure 2 (0.4) 3 (0.7) — —
Death of unknown cause 8 (1.7) 14 (3.2) — —
Death from noncardiovascular cause 18 (3.9) 15 (3.4) — —
Heart transplantation 0 1 (0.2) — —
Shunt thrombosis† 27 (5.8) 21 (4.8) 1.0 –16.1 (–105.3 to 34.4) 0.61
Decreased murmur and increased cyanosis 16/27 (59.3) 14/21 (66.7) — —
Impairment of shunt flow 24/27 (88.9) 19/21 (90.5) — —
Surgical observation 6/27 (22.2) 2/21 (9.5) — —
Postmortem observation 2/27 (7.4) 0 — —
Progressive cyanosis requiring a procedure 19/27 (70.4) 10/21 (47.6) — —
Cardiac procedure at <120 days of age, after 
thrombotic event
21 (4.5) 14 (3.2) 1.3 –38.0 (–171.4 to 29.8) 0.35
* The primary end point was a composite of death or heart transplantation, shunt thrombosis requiring intervention, or a cardiac procedure 
performed before 120 days of age, after an event adjudicated as thrombotic. Only the first event was counted.
† Shunt thrombosis was confirmed by detection of one or more of the following: decreased murmur and increased cyanosis; impairment of 
shunt flow observed on Doppler echocardiography, on angiography during surgery, or on magnetic resonance imaging or computed tomogra-
phy after death; or progressive cyanosis requiring urgent shunt revision or a  revascularization procedure.
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may be smaller in our study population than in 
a more homogeneous population of adults with 
atherosclerotic cardiovascular disease.
The efficacy of aspirin in preventing shunt 
thrombosis has never been tested in a random-
ized, controlled trial. Nonetheless, aspirin is wide-
ly used for this purpose, and most infants in our 
study received aspirin treatment as part of their 
routine care. Indeed, the results of our post hoc 
analysis are consistent with prospective registry 
data suggesting that aspirin prevents death and 
shunt-related morbidity in patients like ours.6 It is 
possible that clopidogrel would have been effec-
tive had aspirin not been used concomitantly. 
However, the effect of clopidogrel treatment on 
the primary composite end point did not differ 
according to whether aspirin was used concomi-
tantly.
Platelets in neonates, as compared with plate-
lets in older children and adults, have a decreased 
response to standard physiologically relevant ago-
nists, as reflected in decreased aggregation, gran-
ule secretion, and expression of activation mark-
ers after stimulation with adenosine diphosphate 
(ADP), collagen, epinephrine, thromboxane ana-
logues, or low-dose thrombin.17 The baseline mean 
percentage of platelet aggregation after stimu-
lation with 5 μM ADP is approximately 50% in 
adults but approximately 15% in neonates.18 
A clopidogrel dose of 0.2 mg per kilogram, which 
was the dose used in the infants in this trial, pro-
vides a level of inhibition of the baseline response 
that is similar to the level of inhibition provided 
by a dose of 75 mg in an adult (30 to 50% inhi-
bition after stimulation with 5 μM ADP), as deter-
mined in a previous dose-finding trial in infants.18 
However, the normal baseline aggregation rate is 
lower in infants than in adults,19 so blocking ADP 
with clopidogrel may be less protective against 
thrombosis in infants. A low baseline aggregation 
rate could also explain the absence of an increase 
in the risk of bleeding with the clopidogrel dose 
used in this trial. We chose this dose because it 
provided a level of inhibition of baseline platelet 
aggregation in infants that was similar to the level 
in adults and because we believed it provided the 
safest addition to standard postoperative therapy 
in infants with systemic-to-pulmonary-artery 
shunts. However, the results of our trial do not 
preclude the efficacy or safety of higher-dose 
regimens.
In the present study, we established a standard-
ized approach to assessing bleeding events by de-
veloping defined criteria appropriate for use in 
this infant population. This approach has not been 
used in previous trials, and we do not have spe-
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Figure 2. Kaplan–Meier Event Rates for the Primary Efficacy End Point.
The primary efficacy end point was defined as death or heart transplanta-
tion, shunt thrombosis, or a cardiac procedure performed before 120 days 
of age, after an event adjudicated to be thrombotic. CI denotes confidence 
interval, and RRR relative risk reduction.
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Figure 3. Kaplan–Meier Event Rates for Bleeding.
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cific validation of the clinical usefulness or repro-
ducibility of these criteria. Although we did not 
find significant differences in the percentage of 
adverse events between the two study groups, the 
power of our study to detect such differences was 
limited.
There are other important limitations of this 
trial. Information about the young infants who 
were screened and excluded was not collected, 
limiting insight into the generalizability of our 
study population. Aspirin therapy was the standard 
of care for infants with systemic-to-pulmonary-
artery shunts at most centers, so we could not use 
a factorial design in which patients were random-
ly assigned to receive aspirin with clopidogrel or 
clopidogrel alone. Despite the independent ad-
judication of thrombotic events, the clinical di-
agnosis of shunt occlusion and its mechanisms 
is imprecise. We did not collect data on the many 
postrandomization factors, such as the number 
of central catheters or total days in the cardiac 
intensive care unit, which might increase throm-
botic complications. However, because these 
factors occurred after randomization, we believe 
it is unlikely that they affected the results. The 
estimated treatment effects had large confi-
dence intervals. This highlights the challenges 
of conducting a trial of treatment in children 
with a rare disease; despite an aggressive enroll-
ment campaign spread over 134 sites in 31 coun-
tries, our study did not have adequate statistical 
power to test the equivalence of clopidogrel and 
placebo.
In conclusion, we found no benefit of clopido-
grel, as compared with placebo, in reducing the 
rate of death for any cause or shunt-related mor-
bidity, particularly shunt thrombosis, among in-
fants with congenital heart disease palliated with 
a systemic-to-pulmonary-artery shunt.
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